- Home
- TKNO vs ALT Comparison
TKNO vs ALT Comparison
Compare TKNO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- ALT
- Stock Information
- Founded
- TKNO 1996
- ALT 1997
- Country
- TKNO United States
- ALT United States
- Employees
- TKNO N/A
- ALT N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- ALT Health Care
- Exchange
- TKNO Nasdaq
- ALT Nasdaq
- Market Cap
- TKNO 356.4M
- ALT 292.8M
- IPO Year
- TKNO 2021
- ALT N/A
- Fundamental
- Price
- TKNO $4.34
- ALT $3.61
- Analyst Decision
- TKNO
- ALT Strong Buy
- Analyst Count
- TKNO 0
- ALT 6
- Target Price
- TKNO N/A
- ALT $18.20
- AVG Volume (30 Days)
- TKNO 318.0K
- ALT 3.5M
- Earning Date
- TKNO 08-07-2025
- ALT 08-15-2025
- Dividend Yield
- TKNO N/A
- ALT N/A
- EPS Growth
- TKNO N/A
- ALT N/A
- EPS
- TKNO N/A
- ALT N/A
- Revenue
- TKNO $38,250,000.00
- ALT $20,000.00
- Revenue This Year
- TKNO $8.73
- ALT N/A
- Revenue Next Year
- TKNO $16.53
- ALT $346,228.97
- P/E Ratio
- TKNO N/A
- ALT N/A
- Revenue Growth
- TKNO 3.79
- ALT N/A
- 52 Week Low
- TKNO $3.34
- ALT $2.90
- 52 Week High
- TKNO $10.37
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- TKNO 36.34
- ALT 34.75
- Support Level
- TKNO $5.03
- ALT $3.58
- Resistance Level
- TKNO $5.31
- ALT $4.39
- Average True Range (ATR)
- TKNO 0.35
- ALT 0.19
- MACD
- TKNO 0.01
- ALT -0.00
- Stochastic Oscillator
- TKNO 15.75
- ALT 4.65
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.